Source comparison
CJC-1295 no DAC & Ipamorelin Cycle Length: Protocol Comparison
Different cycle structures suit different research objectives. The table below compares the three most common approaches based on receptor management, total peptide exposure, and logistical complexity. Standard 12-week 12 weeks continuous 4 weeks full washout
This comparison does not assign a generated winner or score.
- Different cycle structures suit different research objectives. The table below compares the three most common approaches based on receptor management, total peptide exposure, and logistical complexity.
- Standard 12-week
- 12 weeks continuous
- 4 weeks full washout
- Low. Stays within receptor responsiveness window
- First-time protocols, general research, baseline data collection
- Most evidence-based structure with clearest receptor recovery data. Reliable and reproducible.
- Split 10/2/10
- 10 weeks, 2-week break, 10 weeks
- 4 weeks full washout after second block
- Moderate. Mid-cycle break may restore 70–75% receptor capacity
- Extended studies requiring >12 weeks total exposure
- Adds complexity for modest receptor benefit. Limited clinical validation compared to standard structure.
- Dose-cycling
- 12 weeks with 50% dose reduction at weeks 7–9
- Moderate to high. Partial stimulation still present during 'break'
- Protocols testing dose-response relationships
- Unproven approach. No strong evidence it outperforms clean breaks. Harder to control variables.
- Extended 16-week
- 16 weeks continuous
- 6 weeks full washout
- High. Receptor downregulation typically begins week 10–12
- Not recommended except for specific long-duration studies
- Weeks 13–16 deliver minimal additional benefit while prolonging receptor desensitization. Inefficient.
- The standard 12-week cycle remains the gold standard because it aligns with endocrine physiology rather than fighting it. Growth hormone receptor responsiveness stays high through week 8, begins tapering around week 10, and reaches diminishing returns by week 12–13. Stopping at 12 weeks captures the full benefit window without wasting peptides on a desensitized system. The 4-week washout then restores receptor density to >95% of baseline levels, meaning your second cycle starts with nearly the same response magnitude as your first.